
Sign up to save your podcasts
Or


Dr Melissa Johnson from Sarah Cannon Research Institute in Nashville, Tennessee, discusses available data with antibody-drug conjugates with established and investigational targets in patients with non-small cell lung cancer.
By Dr. Neil Love4.4
3030 ratings
Dr Melissa Johnson from Sarah Cannon Research Institute in Nashville, Tennessee, discusses available data with antibody-drug conjugates with established and investigational targets in patients with non-small cell lung cancer.

43,693 Listeners

316 Listeners

2,061 Listeners

68 Listeners

73 Listeners

14 Listeners

17 Listeners

12 Listeners

0 Listeners

120 Listeners

58 Listeners

45 Listeners

26 Listeners

57 Listeners

192 Listeners

44 Listeners

0 Listeners

3 Listeners